Carotid and Renal Artery Stents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: December 19, 2023 Report Code: GDME1687EPD-ST

Select Item

Carotid and Renal Artery Stents Pipeline Market Report Overview

Carotid artery stents are expandable tubes that are implanted in narrowed carotid arteries to increase the flow of blood. Likewise, renal artery stents are expandable tubes that are implanted to increase blood flow in the narrowed renal artery.

The Carotid and Renal Artery Stents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Segments ·        Carotid Artery Bare Metal Stents

·        Renal Artery Bare Metal Stents
Key Territories ·        United States

·        China

·        Europe

·        Israel

·        Singapore
Key Regulatory Paths ·        PMA

·        NMPA

·        CE

·        HSA

·        MDL

·        BOPA
Leading Companies ·        Acotec Scientific Holdings Ltd

·        Contego Medical LLC

·        CR Bard Inc

·        Evasc Medical Systems Corp

·        InspireMD Inc

·        MicroPort Scientific Corp
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Carotid and Renal Artery Stents Pipeline Market by Segments

The key segments in the carotid and renal artery stents pipeline market are carotid artery bare metal stents and renal artery bare metal stents. As of December 2023, carotid artery bare metal stents accounted for the highest number of pipeline products.

Carotid and Renal Artery Stents Pipeline Market Analysis by Segments, 2023 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Segments, 2023 (%)

Buy Full Report for More Segment Insights into the Carotid and Renal Artery Stents Pipeline Market
Download a Free Report Sample

Carotid and Renal Artery Stents Pipeline Market Segmentation by Territories

The key territories in the carotid and renal artery stents market are the US, China, Europe, Israel, Singapore, Taiwan, and Canada among others. As of December 2023, the US accounted for the highest number of pipeline products.

Carotid and Renal Artery Stents Pipeline Market Analysis by Territories, 2023 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Territories, 2023 (%)
Buy the Full Report for More Territory Insights into the Carotid and Renal Artery Stents Pipeline Market
Download a Free Report Sample

Carotid and Renal Artery Stents Pipeline Market Segmentation by Regulatory Paths

The key regulatory paths in the carotid and renal artery stents pipeline market are PMA, NMPA, CE, HSA, MDL, and BOPA. As of December 2023, PMA is the most followed pathway for pipeline products in the market.

Carotid and Renal Artery Stents Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Carotid and Renal Artery Stents Pipeline Market Analysis by Regulatory Paths, 2023 (%)
Buy the Full Report for More Regulatory Path Insights into the Carotid and Renal Artery Stents Pipeline Market
Download A Free Report Sample

Carotid and Renal Artery Stents Pipeline Market – Competitive Landscape

The key companies in the carotid and renal artery stents pipeline market are:

  • Acotec Scientific Holdings Ltd
  • Contego Medical LLC
  • CR Bard Inc
  • Evasc Medical Systems Corp
  • InspireMD Inc
  • MicroPort Scientific Corp
  • Others

Contego Medical LLC (Contego): Contego operates as a medical device company that develops embolic protection devices for the treatment of cardiovascular and peripheral vascular procedures. Its integrated embolic protection (IEP) platform is designed such that embolization is suitable for all angioplasty and stenting procedures in vascular beds such as carotid, peripheral, and coronary arteries.

Carotid and Renal Artery Stents Pipeline Market Analysis by Companies, 2023

Carotid and Renal Artery Stents Pipeline Market Analysis by Companies, 2023
Buy the Full Report for More Company Insights into the Carotid and Renal Artery Stents Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Carotid and Renal Artery Stents Pipeline Market Segments Outlook

  • Carotid Artery Bare Metal Stents
  • Renal Artery Bare Metal Stents

Carotid and Renal Artery Stents Pipeline Market Territories Outlook

  • United States
  • China
  • Europe
  • Israel
  • Singapore

Carotid and Renal Artery Stents Pipeline Market Regulatory Paths Outlook

  • PMA
  • NMPA
  • CE
  • HSA
  • MDL
  • BOPA

Scope

This report provides:

  • Extensive coverage of the carotid and renal artery stents under development.

  • Exhaustive list of major pipeline products and their details including product description, licensing and collaboration details, and other developmental activities.

  • Reviews of major players involved in pipeline product development and lists all their pipeline projects.

  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.

  • Provides key clinical trial data related to ongoing clinical trials specific to pipeline products.

  • Recent developments in the segment/industry.

Reasons to Buy

The report will enable you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.

  • Identify and understand important and diverse types of carotid and renal artery stents under development.

  • Develop market-entry and market-expansion strategies.

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Acotec Scientific Holdings Ltd
Contego Medical LLC
CR Bard Inc
Evasc Medical Systems Corp
InspireMD Inc
MicroPort Scientific Corp
Nesstent Ltd.
Palmaz Scientific Inc (Inactive)
SurModics Inc

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 7

2 Introduction 8

2.1 Carotid and Renal Artery Stents Overview 8

3 Products under Development 9

3.1 Carotid and Renal Artery Stents – Pipeline Products by Stage of Development 9

3.2 Carotid and Renal Artery Stents – Pipeline Products by Segment 10

3.3 Carotid and Renal Artery Stents – Pipeline Products by Territory 11

3.4 Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path 12

3.5 Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date 13

3.6 Carotid and Renal Artery Stents – Ongoing Clinical Trials 14

4 Carotid and Renal Artery Stents – Pipeline Products under Development by Companies 15

4.1 Carotid and Renal Artery Stents Companies – Pipeline Products by Stage of Development 15

4.2 Carotid and Renal Artery Stents – Pipeline Products by Stage of Development 16

5 Carotid and Renal Artery Stents Companies and Product Overview 17

5.1 Acotec Scientific Holdings Ltd Company Overview 17

5.1.1 Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

5.2 Contego Medical LLC Company Overview 18

5.2.1 Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

5.3 CR Bard Inc Company Overview 21

5.3.1 CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 21

5.4 Evasc Medical Systems Corp Company Overview 22

5.4.1 Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 22

5.5 InspireMD Inc Company Overview 23

5.5.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.6 MicroPort Scientific Corp Company Overview 29

5.6.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 29

5.7 Nesstent Ltd. Company Overview 30

5.7.1 Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 Palmaz Scientific Inc (Inactive) Company Overview 31

5.8.1 Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31

5.9 SurModics Inc Company Overview 32

5.9.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 32

6 Carotid and Renal Artery Stents- Recent Developments 33

6.1 Nov 27, 2023: Inspiremd Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of Cguard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions 33

6.2 Nov 10, 2023: Microport Appointment of Director 33

6.3 Nov 01, 2023: Contego Medical Announces One-Year Outcomes From the Performance II Carotid Stent Trial 34

6.4 Nov 01, 2023: Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23 35

6.5 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023 37

6.6 Oct 16, 2023: Cordis Issues Statement on the CMS Announcement to Expand Coverage of Carotid Stenting 39

6.7 Oct 09, 2023: Contego Medical enrols first patient in Neuroguard IEPsystem trial 39

6.8 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business 40

6.9 Sep 29, 2023: Barry Slowey Named Vice President and Chief Sustainability Officer 40

6.10 Sep 21, 2023: Microport Scientific Corp. Announces 2023 Interim Report 41

6.11 Sep 15, 2023: Amber Beauchamp Named Vice President of Global Human Resources 43

6.12 Aug 31, 2023: InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 43

6.13 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair 44

6.14 Aug 24, 2023: Endologix Announces that Lucas Buchanan Joins Board of Directors 44

6.15 Aug 11, 2023: W. L. Gore & Associates to Present New Mosa Paper At Gvsets Conference 45

6.16 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024 45

6.17 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility 46

6.18 Jul 11, 2023: Microport Scientific Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 46

6.19 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023 46

6.20 Apr 26, 2023: MicroPort announces annual results for 2022 46

6.21 Apr 12, 2023: Medtronic has a layoff in California 47

6.22 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company 47

6.23 Feb 06, 2023: Surmodics Lays off 58 employees 47

6.24 Feb 06, 2023: Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance 47

6.25 Jan 31, 2023: Surmodics to Host Virtual Annual Meeting of Shareholders 49

7 Appendix 50

7.1 Methodology 50

7.2 About GlobalData 53

7.3 Contact Us 53

7.4 Disclaimer 53

Table

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development 9

Carotid and Renal Artery Stents – Pipeline Products by Segment 10

Carotid and Renal Artery Stents – Pipeline Products by Territory 11

Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path 12

Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date 13

Carotid and Renal Artery Stents – Ongoing Clinical Trials 14

Carotid and Renal Artery Stents Companies – Pipeline Products by Stage of Development 15

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development 16

Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

Carotid Stent – Product Status 17

Carotid Stent – Product Description 17

Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 18

Neuroguard IEP System – Product Status 18

Neuroguard IEP System – Product Description 18

Contego Medical LLC – Ongoing Clinical Trials Overview 19

Neuroguard IEP System – Protection Against Emboli During Carotid Artery Stenting Using a 3-in-1 Delivery System Comprised of a Post-dilation Balloon, Integrated Embolic Filter and a Novel Carotid Stent II 20

Neuroguard IEP System – Protection Against Emboli During caRotid Artery Stenting Using a Neuroguard IEP® Direct 3-in-1 Delivery System Comprised oF a pOst-dilation Balloon, integRated eMbolic Filter, and A Novel Carotid stEnt – the PERFORMANCE III Study 20

CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 21

VIVEXX Carotid Stent – Product Status 21

VIVEXX Carotid Stent – Product Description 21

Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 22

ROSS – Renal Ostial Stent System – Product Status 22

ROSS – Renal Ostial Stent System – Product Description 22

InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 23

CGuard Embolic Prevention System – Product Status 23

CGuard Embolic Prevention System – Product Description 24

Next Gen CGuard – 5F – Product Status 24

Next Gen CGuard – 5F – Product Description 24

RGuard Renal – Product Status 25

RGuard Renal – Product Description 25

InspireMD Inc – Ongoing Clinical Trials Overview 26

CGuard Embolic Prevention System – A Multicenter, Single-arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting 27

CGuard Embolic Prevention System – Acute Stroke of Carotid Artery Bifurcation Origin Treated with Use of the Micronet-covered CGUARD Stent Under Transient Flow Reversal Linked with Thrombus Retrieval: SAFEGUARD-STROKE Study 27

CGuard Embolic Prevention System – An Early Feasibility Study (EFS) Assessing the CGuard Embolic Prevention Carotid Stent to Treat Severe Carotid Stenosis or Occlusion 27

CGuard Embolic Prevention System – Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND 28

CGuard Embolic Prevention System – OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study 28

CGuard Embolic Prevention System – Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL) 28

MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 29

Taurus Carotid Stent – Product Status 29

Taurus Carotid Stent – Product Description 29

Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview 30

NesStent’s Stent – Carotid Bifurcation – Product Status 30

NesStent’s Stent – Carotid Bifurcation – Product Description 30

Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31

Micro-Mesh Covered Carotid Stent – Product Status 31

Micro-Mesh Covered Carotid Stent – Product Description 31

SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Renal Stent System – Product Status 32

Renal Stent System – Product Description 32

Glossary 52

Figures

Carotid and Renal Artery Stents – Pipeline Products by Stage of Development 9

Carotid and Renal Artery Stents – Pipeline Products by Segment 10

Carotid and Renal Artery Stents – Pipeline Products by Territory 11

Carotid and Renal Artery Stents – Pipeline Products by Regulatory Path 12

Carotid and Renal Artery Stents – Pipeline Products by Estimated Approval Date 13

Carotid and Renal Artery Stents – Ongoing Clinical Trials 14

Frequently asked questions

Carotid and Renal Artery Stents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Carotid and Renal Artery Stents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Carotid and Renal Artery Stents reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Carotid and Renal Artery Stents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Carotid and Renal Artery Stents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more